VB vs. SCHA: Which Small-Cap ETF Is the Better Buy for Investors?

Both Vanguard VB and Schwab SCHA charge ultra-low 0.03% expense ratios, but SCHA delivered higher 1-year total returns (34.18% vs 23.75% for VB). The outperformance is largely driven by SCHA’s ~6% concentration in Sandisk, whose shares have risen more than 30-fold over the past year on AI-driven memory demand, while VB avoids Sandisk. The main risk is concentration timing: Sandisk’s likely move into mega-cap at the next index reconstitution should reduce SCHA’s advantage.

Analysis

The real signal here is not “small-cap outperformance,” it’s benchmark leakage: SCHA is temporarily a concentrated momentum wrapper, while VB is closer to clean small-cap beta. That matters because passive flows create a lagged buyer/seller imbalance around reclassification events; once the oversized position is removed, SCHA’s return profile should mechanically lose a major source of excess performance even if the underlying small-cap tape is unchanged.

The immediate winners are the non-concentrated vehicles and the broader small-cap names that are not dependent on one crowded factor trade. VB should be the better choice for investors seeking duration on a broadening domestic-growth cycle, while SCHA is effectively a short-term call option on continued strength in the dominant semiconductor exposure. On the loser side, the concentrated name faces a future air pocket as index demand fades; the second-order effect is that relative performance can compress faster than fundamentals because the buyer base is forced, not discretionary.

Catalyst timing is key: over days to weeks, momentum can still override structure and keep SCHA ahead; over 1-3 months, reconstitution expectations should start to matter; over 6-18 months, the cleaner signal is whether small-cap breadth improves outside of semis. The thesis breaks if the concentrated stock keeps compounding fast enough to offset the index exit, or if small-cap breadth remains weak and the market continues paying up for the same tech beta.

Consensus is missing that the fee debate is irrelevant here: identical expense ratios mean the trade is really about hidden factor concentration and rebalancing mechanics. That suggests the recent SCHA outperformance is partly backward-looking and may be overowned by investors who think they are buying diversified small-cap exposure.

Key Decisions for Investors

• Long VB / short SCHA as a relative-value pair into the next reconstitution window; target is mean reversion in the concentration premium over 1-3 months, with risk limited to continued momentum in the concentrated name.
• Avoid initiating fresh SCHA longs until after reconstitution; if already long, consider trimming into strength and rotating to VB to reduce single-name dependency.
• Set a watchlist alert on SNDK around the rebalance date: if the stock remains >5% of SCHA close to removal, expect technical downside in SCHA from forced selling and lower marginal demand.
• For traders willing to express the technical unwind, use a bearish options structure on SNDK into reconstitution (put spread rather than outright short) to capture the risk of index-demand evaporation while limiting squeeze risk.